Recommendations and guidelines for the treatment of pneumonia in Taiwan

Journal of Microbiology, Immunology and Infection

Volumn 52, Issue 1, 2019, Pages 172-199

  Chou, Chih Chen ^a   Shen, Ching Fen ^b   Chen, Su Jung ^c,d   Chen, Hsien Meng ^e   Wang, Yung Chih ^f   Chang, Wei Shuo ^g   Chang, Ya Ting ^h   Chen, Wei Yu ⁱ   Huang, Ching Ying ^j   Kuo, Ching Chia ^k   Li, Ming Chi ^b   Lin, Jung Fu ^k   Lin, Shih Ping ^l   Ting, Shih Wen ^k   Weng, Tzu Chieh ^m   Wu, Ping Sheng ⁿ   Wu, Un In ^o   Lin, Pei Chin ^a,p   Lee, Susan Shin Jung ^a,d   Chen, Yao Shen ^a,d   Liu, Yung Ching ^q   Chuang, Yin Ching ^m   Yu, Chong Jen ^r   Huang, Li Ming ^o   Lin, Meng Chih ^s   more..

^a KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^f TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^g CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^h KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

ⁱ SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^j MACKAY MEMORIAL HOSPITAL   (Taiwan)

^k CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^l TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^m CHI MEI MEDICAL CENTER   (Taiwan)

ⁿ Taipei Tzu Chi Hospital   (Taiwan)

^o NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^p KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^q TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^r NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^s CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

more..

Author keywords

Guidelines; Pneumonia; Taiwan; Treatment

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ACINETOBACTER; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BURKHOLDERIA PSEUDOMALLEI; CARBAPENEM RESISTANCE; CHILD; CHILD HOSPITALIZATION; CHLAMYDIA PNEUMONIAE; CHLAMYDIAL PNEUMONIA; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; DISEASE SEVERITY; DRUG DOSE ESCALATION; ENTEROBACTERIACEAE; EPIDEMIOLOGICAL DATA; HAEMOPHILUS INFLUENZAE; HEALTH CARE ASSOCIATED PNEUMONIA; HEMODIALYSIS ASSOCIATED PNEUMONIA; HEMODYNAMIC PARAMETERS; HOSPITAL ACQUIRED PNEUMONIA; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; INFECTION RISK; INTENSIVE CARE UNIT; LEGIONELLA; LETTER; MEDICAL HISTORY; MORAXELLA CATARRHALIS; MORTALITY RISK; MULTIDRUG RESISTANCE; MYCOPLASMA PNEUMONIA; MYCOPLASMA PNEUMONIAE; NONHUMAN; NURSING HOME ASSOCIATED PNEUMONIA; OUTPATIENT CARE; PEDIATRIC PATIENT; PNEUMONIA; PRACTICE GUIDELINE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PNEUMONIA; RISK FACTOR; STAPHYLOCOCCAL PNEUMONIA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; TAIWAN; TIME OUT (HEALTHCARE); VENTILATOR ASSOCIATED PNEUMONIA; EPIDEMIOLOGY; EVIDENCE BASED MEDICINE; INTENSIVE CARE; ORGANIZATION AND MANAGEMENT;

ADULT; ANTI-BACTERIAL AGENTS; CHILD; CRITICAL CARE; EVIDENCE-BASED MEDICINE; GRADE APPROACH; HUMANS; PNEUMONIA; TAIWAN;

EID: 85059437821     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2018.11.004     Document Type: Letter

References (187)

1. Ministry of Health and Welfare. The News Press of Ministry of Health and Welfare. Theme: Taiwan's Leading Causes of Death in 2017. https://www.mohw.gov.tw/cp-3961-41763-2.html [Accessed 12 December 2018].
2. National Institute for Health and Care Excellence (Nice). NICE clinical guideline [CG191]: pneumonia in adults: diagnosis and management. https://www.nice.org.uk/guidance/cg191 [Accessed 6 November 2018].
3. Eccles, S., Pincus, C., Higgins, B., Woodhead, M., Guideline Development Group. Diagnosis and management of community and hospital acquired pneumonia in adults: summary of NICE guidance. BMJ, 349, 2014, g6722.
4. Mandell, L.A., Wunderink, R.G., Anzueto, A., Bartlett, J.G., Campbell, G.D., Dean, N.C., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44:Suppl. 2 (2007), S27–S72.
5. Kalil, A.C., Metersky, M.L., Klompas, M., Muscedere, J., Sweeney, D.A., Palmer, L.B., et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society. Clin Infect Dis 63 (2016), e61–e111.
6. Cao, B., Huang, Y., She, D.Y., Cheng, Q.J., Fan, H., Tian, X.L., et al. Diagnosis and treatment of community-acquired pneumonia in adults: 2016 clinical practice guidelines by the Chinese Thoracic Society, Chinese Medical Association. Clin Respir J 12 (2018), 1320–1360.
7. Gupta, D., Agarwal, R., Aggarwal, A.N., Singh, N., Mishra, N., Khilnani, G.C., et al. Guidelines for diagnosis and management of community- and hospital-acquired pneumonia in adults: joint ICS/NCCP(I) recommendations. Lung India 29 (2012), S27–S62.
8. Boyles, T.H., Brink, A., Calligaro, G.L., Cohen, C., Dheda, K., Maartens, G., et al. South African guideline for the management of community-acquired pneumonia in adults. J Thorac Dis 9 (2017), 1469–1502.
9. Torres, A., Niederman, M.S., Chastre, J., Ewig, S., Fernandez-Vandellos, P., Hanberger, H., et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia. Eur Respir J, 50, 2017, 1700582.
10. Wiersinga, W.J., Bonten, M.J., Boersma, W.G., Jonkers, R.E., Aleva, R.M., Kullberg, B.J., et al. Management of community-acquired pneumonia in adults: 2016 guideline update from the Dutch working party on antibiotic policy (SWAB) and Dutch association of chest physicians (NVALT). Neth J Med 76 (2018), 4–13.
11. The Infectious Diseases Society of the Republic of China. Guidelines on antimicrobial therapy of pneumonia in Taiwan. J Microbiol Immunol Infect 32 (1999), 292–294.
12. Infectious diseases society of Taiwan, Taiwan society of pulmonary and critical medicine, medical foundation in memory of Dr. Deh-Lin Cheng, foundation of professor Wei-Chuan Hsieh for infectious diseases Research education, C. Y. Lee's Research foundation for pediatric infectious diseases vaccines. Guidelines on antimicrobial therapy of pneumonia in adults in Taiwan, revised 2006. J Microbiol Immunol Infect 40 (2007), 279–283.
13. Guyatt, G.H., Oxman, A.D., Vist, G.E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336 (2008), 924–926.
14. Guyatt, G.H., Oxman, A.D., Schunemann, H.J., Tugwell, P., Knottnerus, A., GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol 64 (2011), 380–382.
15. American Thoracic Society/Infectious Diseases Society of America (Ats/Idsa). Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171 (2005), 388–416.
16. Musher, D.M., Thorner, A.R., Community-acquired pneumonia. N Engl J Med 371 (2014), 1619–1628.
17. Said, M.A., Johnson, H.L., Nonyane, B.A., Deloria-Knoll, M., O'brien, K.L., et al., Agedd Adult Pneumococcal Burden Study Team. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One, 8, 2013, e60273.
18. Jain, S., Self, W.H., Wunderink, R.G., Fakhran, S., Balk, R., Bramley, A.M., et al. Community-acquired pneumonia requiring hospitalization among U.S. Adults. N Engl J Med 373 (2015), 415–427.
19. Gadsby, N.J., Russell, C.D., Mchugh, M.P., Mark, H., Conway Morris, A., Laurenson, I.F., et al. Comprehensive molecular testing for respiratory pathogens in community-acquired pneumonia. Clin Infect Dis 62 (2016), 817–823.
20. Cilloniz, C., Ewig, S., Polverino, E., Marcos, M.A., Esquinas, C., Gabarrus, A., et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax 66 (2011), 340–346.
21. Johansson, N., Kalin, M., Tiveljung-Lindell, A., Giske, C.G., Hedlund, J., Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis 50 (2010), 202–209.
22. Song, J.H., Oh, W.S., Kang, C.I., Chung, D.R., Peck, K.R., Ko, K.S., et al. Epidemiology and clinical outcomes of community-acquired pneumonia in adult patients in Asian countries: a prospective study by the Asian network for surveillance of resistant pathogens. Int J Antimicrob Agents 31 (2008), 107–114.
23. Song, J.U., Park, H.K., Kang, H.K., Lee, J., Proposed risk factors for infection with multidrug-resistant pathogens in hemodialysis patients hospitalized with pneumonia. BMC Infect Dis, 17, 2017, 681.
24. Lauderdale, T.L., Chang, F.Y., Ben, R.J., Yin, H.C., Ni, Y.H., Tsai, J.W., et al. Etiology of community acquired pneumonia among adult patients requiring hospitalization in Taiwan. Respir Med 99 (2005), 1079–1086.
25. Ngeow, Y.F., Suwanjutha, S., Chantarojanasriri, T., Wang, F., Saniel, M., Alejandria, M., et al. An Asian study on the prevalence of atypical respiratory pathogens in community-acquired pneumonia. Int J Infect Dis 9 (2005), 144–153.
26. Yen, M.Y., Hu, B.S., Chen, Y.S., Lee, S.S., Lin, Y.S., Wann, S.R., et al. A prospective etiologic study of community-acquired pneumonia in Taiwan. J Formos Med Assoc 104 (2005), 724–730.
27. Wu, C.L., Ku, S.C., Yang, K.Y., Fang, W.F., Tu, C.Y., Chen, C.W., et al. Antimicrobial drug-resistant microbes associated with hospitalized community-acquired and healthcare-associated pneumonia: a multi-center study in Taiwan. J Formos Med Assoc 112 (2013), 31–40.
28. Lee, Y.T., Chen, S.C., Chan, K.C., Wu, T.C., Tsao, S.M., Chan, C.H., Impact of infectious etiology on the outcome of Taiwanese patients hospitalized with community acquired pneumonia. J Infect Dev Ctries 7 (2013), 116–124.
29. Hu, H.C., Huang, C.C., Tsai, Y.H., Lee, C.H., Hsieh, M.J., Outcome analysis of patients requiring mechanical ventilation with severe community-acquired pneumonia and identified bacterial pathogens. Chang Gung Med J 28 (2005), 229–236.
30. Wu, C.L., Lin, F.J., Lee, S.Y., Lee, C.H., Peng, M.J., Chen, P.J., et al. Early evolution of arterial oxygenation in severe community-acquired pneumonia: a prospective observational study. J Crit Care 22 (2007), 129–136.
31. Tseng, J.S., Chan, M.C., Hsu, J.Y., Kuo, B.I., Wu, C.L., Procalcitonin is a valuable prognostic marker in ARDS caused by community-acquired pneumonia. Respirology 13 (2008), 505–509.
32. Peto, L., Nadjm, B., Horby, P., Ngan, T.T., Van Doorn, R., Van Kinh, N., et al. The bacterial aetiology of adult community-acquired pneumonia in Asia: a systematic review. Trans R Soc Trop Med Hyg 108 (2014), 326–337.
33. Wu, C.L., Chan, M.C., Chang, G.C., Lee, Y.L., Chin, C.S., Chang, K.M., et al. Etiology and cytokine expression in patients requiring mechanical ventilation due to severe community-acquired pneumonia. J Formos Med Assoc 105 (2006), 49–55.
34. Chou, D.W., Chung, K.M., Chen, C.H., Cheung, B.M., Bacteremic melioidosis in southern Taiwan: clinical characteristics and outcome. J Formos Med Assoc 106 (2007), 1013–1022.
35. Kung, C.T., Li, C.J., Hung, S.C., Ko, S.F., Chen, M.C., Lee, C.H., et al. Acute melioid community-acquired pneumonia. Int J Infect Dis 15 (2011), e627–e630.
36. Tsay, R.W., Chang, F.Y., Serious complications in scrub typhus. J Microbiol Immunol Infect 31 (1998), 240–244.
37. Lai, C.H., Chang, L.L., Lin, J.N., Chen, W.F., Wei, Y.F., Chiu, C.T., et al. Clinical characteristics of Q fever and etiology of community-acquired pneumonia in a tropical region of southern Taiwan: a prospective observational study. PLoS One, 9, 2014, e102808.
38. Freire, A.T., Melnyk, V., Kim, M.J., Datsenko, O., Dzyublik, O., Glumcher, F., et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 68 (2010), 140–151.
39. Barriere, S.L., Challenges in the design and conduct of clinical trials for hospital-acquired pneumonia and ventilator-associated pneumonia: an industry perspective. Clin Infect Dis 51:Suppl. 1 (2010), S4–S9.
40. Martin-Loeches, I., Deja, M., Koulenti, D., Dimopoulos, G., Marsh, B., Torres, A., et al. Potentially resistant microorganisms in intubated patients with hospital-acquired pneumonia: the interaction of ecology, shock and risk factors. Intensive Care Med 39 (2013), 672–681.
41. Sievert, D.M., Ricks, P., Edwards, J.R., Schneider, A., Patel, J., Srinivasan, A., et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2009–2010. Infect Control Hosp Epidemiol 34 (2013), 1–14.
42. Weiner, L.M., Webb, A.K., Limbago, B., Dudeck, M.A., Patel, J., Kallen, A.J., et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2011–2014. Infect Control Hosp Epidemiol 37 (2016), 1288–1301.
43. Jones, R.N., Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis 51:Suppl. 1 (2010), S81–S87.
44. Chung, D.R., Song, J.H., Kim, S.H., Thamlikitkul, V., Huang, S.G., Wang, H., et al. High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia. Am J Respir Crit Care Med 184 (2011), 1409–1417.
45. Taiwan Centers for Disease Control, Annual report of nosocomial infections surveillance system (2017). 2018 https://www.syndriver.com/portal/#/sharing/e88a07ed3cbf4d4a93e367f9ce6384fa. (Accessed 7 November 2018)
46. Wang, P.H., Wang, H.C., Risk factors to predict drug-resistant pathogens in hemodialysis-associated pneumonia. BMC Infect Dis, 16, 2016, 377.
47. Fang, W.F., Yang, K.Y., Wu, C.L., Yu, C.J., Chen, C.W., Tu, C.Y., et al. Application and comparison of scoring indices to predict outcomes in patients with healthcare-associated pneumonia. Crit Care, 15, 2011, R32.
48. Berman, S.J., Johnson, E.W., Nakatsu, C., Alkan, M., Chen, R., Leduc, J., Burden of infection in patients with end-stage renal disease requiring long-term dialysis. Clin Infect Dis 39 (2004), 1747–1753.
49. Slinin, Y., Foley, R.N., Collins, A.J., Clinical epidemiology of pneumonia in hemodialysis patients: the USRDS waves 1, 3, and 4 study. Kidney Int 70 (2006), 1135–1141.
50. Lee, J.H., Moon, J.C., Clinical characteristics of patients with hemodialysis-associated pneumonia compared to patients with non-hemodialysis community-onset pneumonia. Respir Med 111 (2016), 84–90.
51. Kawasaki, S., Aoki, N., Kikuchi, H., Nakayama, H., Saito, N., Shimada, H., et al. Clinical and microbiological evaluation of hemodialysis-associated pneumonia (HDAP): should HDAP be included in healthcare-associated pneumonia?. J Infect Chemother 17 (2011), 640–645.
52. Lim, C.W., Choi, Y., An, C.H., Park, S.J., Hwang, H.J., Chung, J.H., et al. Facility characteristics as independent prognostic factors of nursing home-acquired pneumonia. Korean J Intern Med 31 (2016), 296–304.
53. Dhawan, N., Pandya, N., Khalili, M., Bautista, M., Duggal, A., Bahl, J., et al. Predictors of mortality for nursing home-acquired pneumonia: a systematic review. Biomed Res Int, 2015, 2015, 285983.
54. Webb, B.J., Dangerfield, B.S., Pasha, J.S., Agrwal, N., Vikram, H.R., Guideline-concordant antibiotic therapy and clinical outcomes in healthcare-associated pneumonia. Respir Med 106 (2012), 1606–1612.
55. Costelloe, C., Metcalfe, C., Lovering, A., Mant, D., Hay, A.D., Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ, 340, 2010, c2096.
56. Kuster, S.P., Rudnick, W., Shigayeva, A., Green, K., Baqi, M., Gold, W.L., et al. Previous antibiotic exposure and antimicrobial resistance in invasive pneumococcal disease: results from prospective surveillance. Clin Infect Dis 59 (2014), 944–952.
57. Deantonio, R., Yarzabal, J.P., Cruz, J.P., Schmidt, J.E., Kleijnen, J., Epidemiology of community-acquired pneumonia and implications for vaccination of children living in developing and newly industrialized countries: a systematic literature review. Hum Vaccin Immunother 12 (2016), 2422–2440.
58. Baqui, A.H., El Arifeen, S., Saha, S.K., Persson, L., Zaman, K., Gessner, B.D., et al. Effectiveness of Haemophilus influenzae type B conjugate vaccine on prevention of pneumonia and meningitis in Bangladeshi children: a case-control study. Pediatr Infect Dis J 26 (2007), 565–571.
59. Pilishvili, T., Lexau, C., Farley, M.M., Hadler, J., Harrison, L.H., Bennett, N.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 201 (2010), 32–41.
60. Chen, H.H., Li, H.C., Su, L.H., Chiu, C.H., Fluoroquinolone-nonsusceptible Streptococcus pneumoniae isolates from a medical center in the pneumococcal conjugate vaccine era. J Microbiol Immunol Infect 50 (2017), 839–845.
61. Chen, C.J., Lin, P.Y., Tsai, M.H., Huang, C.G., Tsao, K.C., Wong, K.S., et al. Etiology of community-acquired pneumonia in hospitalized children in northern Taiwan. Pediatr Infect Dis J 31 (2012), e196–e201.
62. Hsieh, Y.C., Hung, H.M., Huang, Y.C., Huang, L.M., Chi, H., Liu, C.C., et al. Incidence and etiology of hospitalized childhood community-acquired alveolar pneumonia in Taiwan. 35th annual meeting of the European society for paediatric infectious diseases, 2017, ESPID 2017, Madrid, Spain.
63. Wu, H.M., Wong, K.S., Huang, Y.C., Lai, S.H., Tsao, K.C., Lin, Y.J., et al. Macrolide-resistant Mycoplasma pneumoniae in children in Taiwan. J Infect Chemother 19 (2013), 782–786.
64. Wu, P.S., Chang, L.Y., Lin, H.C., Chi, H., Hsieh, Y.C., Huang, Y.C., et al. Epidemiology and clinical manifestations of children with macrolide-resistant Mycoplasma pneumoniae pneumonia in Taiwan. Pediatr Pulmonol 48 (2013), 904–911.
65. Yang, T.I., Chang, T.H., Lu, C.Y., Chen, J.M., Lee, P.I., Huang, L.M., et al. Mycoplasma pneumoniae in pediatric patients: do macrolide-resistance and/or delayed treatment matter?. J Microbiol Immunol Infect, 2018 Oct 9, 10.1016/j.jmii.2018.09.009 pii:S1684-1182(18)30186-5. [Epub ahead of print].
66. Jain, S., Williams, D.J., Arnold, S.R., Ampofo, K., Bramley, A.M., Reed, C., et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med 372 (2015), 835–845.
67. Berg, A.S., Inchley, C.S., Aase, A., Fjaerli, H.O., Bull, R., Aaberge, I., et al. Etiology of pneumonia in a pediatric population with high pneumococcal vaccine coverage: a prospective study. Pediatr Infect Dis J 35 (2016), e69–e75.
68. Lee, M.R., Chen, C.M., Chuang, T.Y., Huang, Y.T., Hsueh, P.R., Capsular serotypes and antimicrobial susceptibilities of Streptococcus pneumoniae causing invasive pneumococcal disease from 2009-2012 with an emphasis on serotype 19A in bacteraemic pneumonia and empyema and beta-lactam resistance. Int J Antimicrob Agents 42 (2013), 395–402.
69. Tsai, H.Y., Chen, Y.H., Liao, C.H., Lu, P.L., Huang, C.H., Lu, C.T., et al. Trends in the antimicrobial susceptibilities and serotypes of Streptococcus pneumoniae: results from the Tigecycline in Vitro Surveillance in Taiwan (TIST) study, 2006-2010. Int J Antimicrob Agents 42 (2013), 312–316.
70. Yuan, J., Mo, B., Ma, Z., Lv, Y., Cheng, S.L., Yang, Y., et al. Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: a phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial. J Microbiol Immunol Infect 52 (2019), 35–44.
71. Yahav, D., Lador, A., Paul, M., Leibovici, L., Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 66 (2011), 1963–1971.
72. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new Boxed Warning. 2013.
73. Garin, N., Genne, D., Carballo, S., Chuard, C., Eich, G., Hugli, O., et al. beta-Lactam monotherapy vs beta-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern Med 174 (2014), 1894–1901.
74. Postma, D.F., Van Werkhoven, C.H., Van Elden, L.J., Thijsen, S.F., Hoepelman, A.I., Kluytmans, J.A., et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med 372 (2015), 1312–1323.
75. Horita, N., Otsuka, T., Haranaga, S., Namkoong, H., Miki, M., Miyashita, N., et al. Beta-lactam plus macrolides or beta-lactam alone for community-acquired pneumonia: a systematic review and meta-analysis. Respirology 21 (2016), 1193–1200.
76. Vardakas, K.Z., Trigkidis, K.K., Falagas, M.E., Fluoroquinolones or macrolides in combination with beta-lactams in adult patients hospitalized with community acquired pneumonia: a systematic review and meta-analysis. Clin Microbiol Infect 23 (2017), 234–241.
77. Kang, C.I., Song, J.H., Oh, W.S., Ko, K.S., Chung, D.R., Peck, K.R., et al. Clinical outcomes and risk factors of community-acquired pneumonia caused by gram-negative bacilli. Eur J Clin Microbiol Infect Dis 27 (2008), 657–661.
78. Torres, A., Blasi, F., Peetermans, W.E., Viegi, G., Welte, T., The aetiology and antibiotic management of community-acquired pneumonia in adults in Europe: a literature review. Eur J Clin Microbiol Infect Dis 33 (2014), 1065–1079.
79. Von Baum, H., Welte, T., Marre, R., Suttorp, N., Ewig, S., Capnetz Study Group. Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: diagnosis, incidence and predictors. Eur Respir J 35 (2010), 598–605.
80. Monso, E., Garcia-Aymerich, J., Soler, N., Farrero, E., Felez, M.A., Anto, J.M., et al. Bacterial infection in exacerbated COPD with changes in sputum characteristics. Epidemiol Infect 131 (2003), 799–804.
81. Cilloniz, C., Gabarrus, A., Ferrer, M., Puig De La Bellacasa, J., Rinaudo, M., Mensa, J., et al. Community-acquired pneumonia due to multidrug- and non-multidrug-resistant Pseudomonas aeruginosa. Chest 150 (2016), 415–425.
82. Chen, T.C., Lu, P.L., Lin, C.Y., Lin, W.R., Chen, Y.H., Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: a systematic review and meta-analysis. Int J Infect Dis 15 (2011), e211–e216.
83. Migliori, G.B., Langendam, M.W., D'ambrosio, L., Centis, R., Blasi, F., Huitric, E., et al. Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones. Eur Respir J 40 (2012), 814–822.
84. Waterer, G.W., Somes, G.W., Wunderink, R.G., Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 161 (2001), 1837–1842.
85. Mufson, M.A., Stanek, R.J., Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978-1997. Am J Med 107 (1999), 34S–43S.
86. Baddour, L.M., Yu, V.L., Klugman, K.P., Feldman, C., Ortqvist, A., Rello, J., et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 170 (2004), 440–444.
87. Martinez, J.A., Horcajada, J.P., Almela, M., Marco, F., Soriano, A., Garcia, E., et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 36 (2003), 389–395.
88. Kalil, A.C., Klompas, M., Haynatzki, G., Rupp, M.E., Treatment of hospital-acquired pneumonia with linezolid or vancomycin: a systematic review and meta-analysis. BMJ Open, 3, 2013, e003912.
89. Liu, C., Bayer, A., Cosgrove, S.E., Daum, R.S., Fridkin, S.K., Gorwitz, R.J., et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 52 (2011), 285–292.
90. Wunderink, R.G., Rello, J., Cammarata, S.K., Croos-Dabrera, R.V., Kollef, M.H., Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124 (2003), 1789–1797.
91. Bernardo, K., Pakulat, N., Fleer, S., Schnaith, A., Utermohlen, O., Krut, O., et al. Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression. Antimicrob Agents Chemother 48 (2004), 546–555.
92. Stevens, D.L., Ma, Y., Salmi, D.B., Mcindoo, E., Wallace, R.J., Bryant, A.E., Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 195 (2007), 202–211.
93. Schonwald, S., Gunjaca, M., Kolacny-Babic, L., Car, V., Gosev, M., Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias. J Antimicrob Chemother 25:Suppl. A (1990), 123–126.
94. File, T.M. Jr., Segreti, J., Dunbar, L., Player, R., Kohler, R., Williams, R.R., et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 41 (1997), 1965–1972.
95. Finch, R., Schurmann, D., Collins, O., Kubin, R., Mcgivern, J., Bobbaers, H., et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 46 (2002), 1746–1754.
96. Zhao, F., Lv, M., Tao, X., Huang, H., Zhang, B., Zhang, Z., et al. Antibiotic sensitivity of 40 Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant isolates from Beijing, China. Antimicrob Agents Chemother 56 (2012), 1108–1109.
97. Roblin, P.M., Hammerschlag, M.R., Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia. Antimicrob Agents Chemother 42 (1998), 194–196.
98. Harris, J.A., Kolokathis, A., Campbell, M., Cassell, G.H., Hammerschlag, M.R., Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children. Pediatr Infect Dis J 17 (1998), 865–871.
99. Hammerschlag, M.R., Roblin, P.M., Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae. Int J Antimicrob Agents 15 (2000), 149–152.
100. Block, S., Hedrick, J., Hammerschlag, M.R., Cassell, G.H., Craft, J.C., Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate. Pediatr Infect Dis J 14 (1995), 471–477.
101. Hammerschlag, M.R., Roblin, P.M., Microbiological efficacy of levofloxacin for treatment of community-acquired pneumonia due to Chlamydia pneumoniae. Antimicrob Agents Chemother, 44, 2000, 1409.
102. Miller, A.C., Erythromycin in legionnaires' disease: a re-appraisal. J Antimicrob Chemother 7 (1981), 217–222.
103. Vergis, E.N., Indorf, A., File, T.M. Jr., Phillips, J., Bates, J., Tan, J., et al. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial. Arch Intern Med 160 (2000), 1294–1300.
104. Genne, D., Siegrist, H.H., Humair, L., Janin-Jaquat, B., De Torrente, A., Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 16 (1997), 783–788.
105. Edelstein, P.H., Edelstein, M.A., Lehr, K.H., Ren, J., In-vitro activity of levofloxacin against clinical isolates of Legionella spp, its pharmacokinetics in Guinea pigs, and use in experimental Legionella pneumophila pneumonia. J Antimicrob Chemother 37 (1996), 117–126.
106. Blazquez Garrido, R.M., Espinosa Parra, F.J., Alemany Frances, L., Ramos Guevara, R.M., Sanchez-Nieto, J.M., Segovia Hernandez, M., et al. Antimicrobial chemotherapy for Legionnaires disease: levofloxacin versus macrolides. Clin Infect Dis 40 (2005), 800–806.
107. Mykietiuk, A., Carratala, J., Fernandez-Sabe, N., Dorca, J., Verdaguer, R., Manresa, F., et al. Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy. Clin Infect Dis 40 (2005), 794–799.
108. Sabria, M., Pedro-Botet, M.L., Gomez, J., Roig, J., Vilaseca, B., Sopena, N., et al. Fluoroquinolones vs macrolides in the treatment of Legionnaires disease. Chest 128 (2005), 1401–1405.
109. Haranaga, S., Tateyama, M., Higa, F., Miyagi, K., Akamine, M., Azuma, M., et al. Intravenous ciprofloxacin versus erythromycin in the treatment of Legionella pneumonia. Intern Med 46 (2007), 353–357.
110. Varner, T.R., Bookstaver, P.B., Rudisill, C.N., Albrecht, H., Role of rifampin-based combination therapy for severe community-acquired Legionella pneumophila pneumonia. Ann Pharmacother 45 (2011), 967–976.
111. Jean, S.S., Hsueh, P.R., Lee, W.S., Chang, H.T., Chou, M.Y., Chen, I.S., et al. Nationwide surveillance of antimicrobial resistance among Haemophilus influenzae and Streptococcus pneumoniae in intensive care units in Taiwan. Eur J Clin Microbiol Infect Dis 28 (2009), 1013–1017.
112. Lau, Y.J., Hsueh, P.R., Liu, Y.C., Shyr, J.M., Huang, W.K., Teng, L.J., et al. Comparison of in vitro activities of tigecycline with other antimicrobial agents against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in Taiwan. Microb Drug Resist 12 (2006), 130–135.
113. Kuo, S.C., Chen, P.C., Shiau, Y.R., Wang, H.Y., Lai, J.F.S., Huang, W., et al. Levofloxacin-resistant haemophilus influenzae, Taiwan, 2004–2010. Emerg Infect Dis 20 (2014), 1386–1390.
114. Hsu, S.F., Lin, Y.T., Chen, T.L., Siu, L.K., Hsueh, P.R., Huang, S.T., et al. Antimicrobial resistance of Moraxella catarrhalis isolates in Taiwan. J Microbiol Immunol Infect 45 (2012), 134–140.
115. Lin, Y.T., Jeng, Y.Y., Chen, T.L., Fung, C.P., Bacteremic community-acquired pneumonia due to Klebsiella pneumoniae: clinical and microbiological characteristics in Taiwan, 2001–2008. BMC Infect Dis, 10, 2010, 307.
116. Ortiz-Ruiz, G., Vetter, N., Isaacs, R., Carides, A., Woods, G.L., Friedland, I., Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies. J Antimicrob Chemother 53:Suppl. 2 (2004), ii59–ii66.
117. Yakovlev, S.V., Stratchounski, L.S., Woods, G.L., Adeyi, B., Mccarroll, K.A., Ginanni, J.A., et al. Ertapenem versus cefepime for initial empirical treatment of pneumonia acquired in skilled-care facilities or in hospitals outside the intensive care unit. Eur J Clin Microbiol Infect Dis 25 (2006), 633–641.
118. Woodhead, M., Blasi, F., Ewig, S., Garau, J., Huchon, G., Ieven, M., et al. Guidelines for the management of adult lower respiratory tract infections-full version. Clin Microbiol Infect 17:Suppl. 6 (2011), E1–E59.
119. Wiersinga, W.J., Currie, B.J., Peacock, S.J., Melioidosis. N Engl J Med 367 (2012), 1035–1044.
120. Foong, Y.C., Tan, M., Bradbury, R.S., Melioidosis: a review. Rural Remote Health, 14, 2014, 2763.
121. Jenney, A.W., Lum, G., Fisher, D.A., Currie, B.J., Antibiotic susceptibility of Burkholderia pseudomallei from tropical northern Australia and implications for therapy of melioidosis. Int J Antimicrob Agents 17 (2001), 109–113.
122. Dance, D., Treatment and prophylaxis of melioidosis. Int J Antimicrob Agents 43 (2014), 310–318.
123. Chaowagul, W., Simpson, A.J., Suputtamongkol, Y., White, N.J., Empirical cephalosporin treatment of melioidosis. Clin Infect Dis, 28, 1999, 1328.
124. White, N.J., Dance, D.A., Chaowagul, W., Wattanagoon, Y., Wuthiekanun, V., Pitakwatchara, N., Halving of mortality of severe melioidosis by ceftazidime. Lancet 2 (1989), 697–701.
125. Simpson, A.J., Suputtamongkol, Y., Smith, M.D., Angus, B.J., Rajanuwong, A., Wuthiekanun, V., et al. Comparison of imipenem and ceftazidime as therapy for severe melioidosis. Clin Infect Dis 29 (1999), 381–387.
126. Cheng, A.C., Fisher, D.A., Anstey, N.M., Stephens, D.P., Jacups, S.P., Currie, B.J., Outcomes of patients with melioidosis treated with meropenem. Antimicrob Agents Chemother 48 (2004), 1763–1765.
127. Chetchotisakd, P., Chierakul, W., Chaowagul, W., Anunnatsiri, S., Phimda, K., Mootsikapun, P., et al. Trimethoprim-sulfamethoxazole versus trimethoprim-sulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis (MERTH): a multicentre, double-blind, non-inferiority, randomised controlled trial. Lancet 383 (2014), 807–814.
128. Cheng, A.C., Chierakul, W., Chaowagul, W., Chetchotisakd, P., Limmathurotsakul, D., Dance, D.A., et al. Consensus guidelines for dosing of amoxicillin-clavulanate in melioidosis. Am J Trop Med Hyg 78 (2008), 208–209.
129. Chaowagul, W., Simpson, A.J., Suputtamongkol, Y., Smith, M.D., Angus, B.J., White, N.J., A comparison of chloramphenicol, trimethoprim-sulfamethoxazole, and doxycycline with doxycycline alone as maintenance therapy for melioidosis. Clin Infect Dis 29 (1999), 375–380.
130. Li, J.Z., Winston, L.G., Moore, D.H., Bent, S., Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med 120 (2007), 783–790.
131. Dimopoulos, G., Matthaiou, D.K., Karageorgopoulos, D.E., Grammatikos, A.P., Athanassa, Z., Falagas, M.E., Short- versus long-course antibacterial therapy for community-acquired pneumonia: a meta-analysis. Drugs 68 (2008), 1841–1854.
132. Uranga, A., Espana, P.P., Bilbao, A., Quintana, J.M., Arriaga, I., Intxausti, M., et al. Duration of antibiotic treatment in community-acquired pneumonia: a multicenter randomized clinical trial. JAMA Intern Med 176 (2016), 1257–1265.
133. Choudhury, G., Mandal, P., Singanayagam, A., Akram, A.R., Chalmers, J.D., Hill, A.T., Seven-day antibiotic courses have similar efficacy to prolonged courses in severe community-acquired pneumonia–a propensity-adjusted analysis. Clin Microbiol Infect 17 (2011), 1852–1858.
134. Athanassa, Z., Makris, G., Dimopoulos, G., Falagas, M.E., Early switch to oral treatment in patients with moderate to severe community-acquired pneumonia: a meta-analysis. Drugs 68 (2008), 2469–2481.
135. Arthur, L.E., Kizor, R.S., Selim, A.G., Van Driel, M.L., Seoane, L., Antibiotics for ventilator-associated pneumonia. Cochrane Database Syst Rev, 10, 2016, CD004267.
136. Kengkla, K., Kongpakwattana, K., Saokaew, S., Apisarnthanarak, A., Chaiyakunapruk, N., Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis. J Antimicrob Chemother 73 (2018), 22–32.
137. Paul, M., Daikos, G.L., Durante-Mangoni, E., Yahav, D., Carmeli, Y., Benattar, Y.D., et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis 18 (2018), 391–400.
138. Morrill, H.J., Pogue, J.M., Kaye, K.S., Laplante, K.L., Treatment options for carbapenem-resistant Enterobacteriaceae infections. Open Forum Infect Dis, 2, 2015, ofv050.
139. Pugh, R., Grant, C., Cooke, R.P., Dempsey, G., Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database Syst Rev, 2015, CD007577.
140. Dimopoulos, G., Poulakou, G., Pneumatikos, I.A., Armaganidis, A., Kollef, M.H., Matthaiou, D.K., Short- vs long-duration antibiotic regimens for ventilator-associated pneumonia: a systematic review and meta-analysis. Chest 144 (2013), 1759–1767.
141. Souza-Oliveira, A.C., Cunha, T.M., Passos, L.B., Lopes, G.C., Gomes, F.A., Roder, D.V., Ventilator-associated pneumonia: the influence of bacterial resistance, prescription errors, and de-escalation of antimicrobial therapy on mortality rates. Braz J Infect Dis 20 (2016), 437–443.
142. Fu, L.Y., Ruthazer, R., Wilson, I., Patel, A., Fox, L.M., Tuan, T.A., et al. Brief hospitalization and pulse oximetry for predicting amoxicillin treatment failure in children with severe pneumonia. Pediatrics 118 (2006), e1822–e1830.
143. Harris, M., Clark, J., Coote, N., Fletcher, P., Harnden, A., Mckean, M., et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax 66:Suppl. 2 (2011), ii1–ii23.
144. Juven, T., Mertsola, J., Waris, M., Leinonen, M., Meurman, O., Roivainen, M., et al. Etiology of community-acquired pneumonia in 254 hospitalized children. Pediatr Infect Dis J 19 (2000), 293–298.
145. Tan, T.Q., Mason, E.O. Jr., Barson, W.J., Wald, E.R., Schutze, G.E., Bradley, J.S., et al. Clinical characteristics and outcome of children with pneumonia attributable to penicillin-susceptible and penicillin-nonsusceptible Streptococcus pneumoniae. Pediatrics 102 (1998), 1369–1375.
146. Mamtani, M., Patel, A., Hibberd, P.L., Tuan, T.A., Jeena, P., Chisaka, N., et al. A clinical tool to predict failed response to therapy in children with severe pneumonia. Pediatr Pulmonol 44 (2009), 379–386.
147. Sebastian, R., Skowronski, D.M., Chong, M., Dhaliwal, J., Brownstein, J.S., Age-related trends in the timeliness and prediction of medical visits, hospitalizations and deaths due to pneumonia and influenza, British Columbia, Canada, 1998–2004. Vaccine 26 (2008), 1397–1403.
148. Jadavji, T., Law, B., Lebel, M.H., Kennedy, W.A., Gold, R., Wang, E.E., A practical guide for the diagnosis and treatment of pediatric pneumonia. Cmaj 156 (1997), S703–S711.
149. Bradley, J.S., Byington, C.L., Shah, S.S., Alverson, B., Carter, E.R., Harrison, C., et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 53 (2011), e25–e76.
150. W.H.O. Guidelines approved by the guidelines review Committee, Recommendations for management of common childhood conditions: evidence for technical update of pocket book recommendations: newborn conditions, dysentery, pneumonia, oxygen use and delivery, Common causes of fever, severe acute malnutrition and supportive care ed. placed published. 2012, World Health Organization https://www.ncbi.nlm.nih.gov/books/NBK138333/. (Accessed 29 January 2018)
151. Lodha, R., Kabra, S.K., Pandey, R.M., Antibiotics for community-acquired pneumonia in children. Cochrane Database Syst Rev, 2013, CD004874.
152. Lodha, R., Randev, S., Kabra, S.K., Oral antibiotics for community acquired pneumonia with chest indrawing in children aged below five years: a systematic review. Indian Pediatr 53 (2016), 489–495.
153. Tramper-Stranders, G.A., Childhood community-acquired pneumonia: a review of etiology and antimicrobial treatment studies. Paediatr Respir Rev 26 (2018), 41–48.
154. Vilas-Boas, A.L., Fontoura, M.S., Xavier-Souza, G., Araujo-Neto, C.A., Andrade, S.C., Brim, R.V., et al. Comparison of oral amoxicillin given thrice or twice daily to children between 2 and 59 months old with non-severe pneumonia: a randomized controlled trial. J Antimicrob Chemother 69 (2014), 1954–1959.
155. Bradley, J.S., Garonzik, S.M., Forrest, A., Bhavnani, S.M., Pharmacokinetics, pharmacodynamics, and Monte Carlo simulation: selecting the best antimicrobial dose to treat an infection. Pediatr Infect Dis J 29 (2010), 1043–1046.
156. Uehara, S., Sunakawa, K., Eguchi, H., Ouchi, K., Okada, K., Kurosaki, T., et al. Japanese guidelines for the management of respiratory infectious diseases in children 2007 with focus on pneumonia. Pediatr Int 53 (2011), 264–276.
157. Shaughnessy, E.E., Stalets, E.L., Shah, S.S., Community-acquired pneumonia in the post 13-valent pneumococcal conjugate vaccine era. Curr Opin Pediatr 28 (2016), 786–793.
158. Ambroggio, L., Test, M., Metlay, J.P., Graf, T.R., Blosky, M.A., Macaluso, M., et al. Beta-lactam versus beta-lactam/macrolide therapy in pediatric outpatient pneumonia. Pediatr Pulmonol 51 (2016), 541–548.
159. Nascimento-Carvalho, C.M., Xavier-Souza, G., Vilas-Boas, A.L., Fontoura, M.H., Barral, A., Puolakkainen, M., et al. Evolution of acute infection with atypical bacteria in a prospective cohort of children with community-acquired pneumonia receiving amoxicillin. J Antimicrob Chemother 72 (2017), 2378–2384.
160. Haider, B.A., Saeed, M.A., Bhutta, Z.A., Short-course versus long-course antibiotic therapy for non-severe community-acquired pneumonia in children aged 2 months to 59 months. Cochrane Database Syst Rev, 2008, CD005976.
161. Greenberg, D., Givon-Lavi, N., Sadaka, Y., Ben-Shimol, S., Bar-Ziv, J., Dagan, R., Short-course antibiotic treatment for community-acquired alveolar pneumonia in ambulatory children: a double-blind, randomized, placebo-controlled trial. Pediatr Infect Dis J 33 (2014), 136–142.
162. Hamano-Hasegawa, K., Morozumi, M., Nakayama, E., Chiba, N., Murayama, S.Y., Takayanagi, R., et al. Comprehensive detection of causative pathogens using real-time PCR to diagnose pediatric community-acquired pneumonia. J Infect Chemother 14 (2008), 424–432.
163. Feigin, R.D., Bacterial pneumonias. Feigin & Cherry's textbook of pediatric infectious diseases, 2009, Saunders/Elsevier, Philadelphia, PA.
164. Lin, T.Y., Hwang, K.P., Liu, C.C., Tang, R.B., Lin, C.Y., Gilbert, G.L., et al. Etiology of empyema thoracis and parapneumonic pleural effusion in Taiwanese children and adolescents younger than 18 years of age. Pediatr Infect Dis J 32 (2013), 419–421.
165. Wei, S.H., Chiang, C.S., Chen, C.L., Chiu, C.H., Pneumococcal disease and use of pneumococcal vaccines in Taiwan. Clin Exp Vaccine Res 4 (2015), 121–129.
166. Wei, S.H., Chiang, C.S., Chiu, C.H., Chou, P., Lin, T.Y., Pediatric invasive pneumococcal disease in Taiwan following a national catch-up program with the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 34 (2015), e71–e77.
167. Chiang, C.S., Chen, Y.Y., Jiang, S.F., Liu, D.P., Kao, P.H., Teng, H.J., et al. National surveillance of invasive pneumococcal diseases in Taiwan, 2008-2012: differential temporal emergence of serotype 19A. Vaccine 32 (2014), 3345–3349.
168. Lee, H.Y., Hsieh, Y.C., Liu, C.C., Huang, Y.C., Chang, K.Y., Chi, H., et al. Invasive pneumococcal pneumonia caused by 13-valent pneumococcal conjugate vaccine types in children with different schedules. J Microbiol Immunol Infect 51 (2018), 199–206.
169. Pallares, R., Capdevila, O., Linares, J., Grau, I., Onaga, H., Tubau, F., et al. The effect of cephalosporin resistance on mortality in adult patients with nonmeningeal systemic pneumococcal infections. Am J Med 113 (2002), 120–126.
170. Taiwan Centers for Disease Control. Taiwan national infectious disease statistics system – invasive Haemophilus influenzae type b (Hib) disease, nationwide, indigenous, and imported, year 1999 – year 2018. https://nidss.cdc.gov.tw/en/SingleDisease.aspx?dc=1&dt=3&disease=3200. [Accessed 7 November 2018].
171. Wang, S.R., Lo, W.T., Chou, C.Y., Chen, Y.Y., Tsai, S.Y., Chu, M.L., et al. Low rate of nasopharyngeal carriage and high rate of ampicillin resistance for Haemophilus influenzae among healthy children younger than 5 years old in northern Taiwan. J Microbiol Immunol Infect 41 (2008), 32–40.
172. Ma, Y.J., Wang, S.M., Cho, Y.H., Shen, C.F., Liu, C.C., Chi, H., et al. Clinical and epidemiological characteristics in children with community-acquired mycoplasma pneumonia in Taiwan: a nationwide surveillance. J Microbiol Immunol Infect 48 (2015), 632–638.
173. Ambroggio, L., Taylor, J.A., Tabb, L.P., Newschaffer, C.J., Evans, A.A., Shah, S.S., Comparative effectiveness of empiric beta-lactam monotherapy and beta-lactam-macrolide combination therapy in children hospitalized with community-acquired pneumonia. J Pediatr 161 (2012), 1097–1103.
174. Leyenaar, J.K., Shieh, M.S., Lagu, T., Pekow, P.S., Lindenauer, P.K., Comparative effectiveness of ceftriaxone in combination with a macrolide compared with ceftriaxone alone for pediatric patients hospitalized with community-acquired pneumonia. Pediatr Infect Dis J 33 (2014), 387–392.
175. Cevey-Macherel, M., Galetto-Lacour, A., Gervaix, A., Siegrist, C.A., Bille, J., Bescher-Ninet, B., et al. Etiology of community-acquired pneumonia in hospitalized children based on WHO clinical guidelines. Eur J Pediatr 168 (2009), 1429–1436.
176. Bradley, J.S., Byington, C.L., Shah, S.S., Alverson, B., Carter, E.R., Harrison, C., et al. Executive summary: the management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 53 (2011), 617–630.
177. CaLS, Institute, Performance standards for antimicrobial susceptibility testing. CLSI document M100-S18. 2008, Clinical and Laboratory Standards Institute.
178. Taiwan C.D.C. Report of drug resistance surveillance of Streptococcus pneumoniae in 2016 in Taiwan. https://nidss.cdc.gov.tw/en/SingleDisease.aspx?dc=1&dt=4&disease=0412. [Accessed 6 November].
179. Cho, Y.C., Chiu, N.C., Huang, F.Y., Huang, D.T., Chang, L., Huang, C.Y., et al. Epidemiology and antimicrobial susceptibility of non-typeable Haemophilus influenzae in otitis media in Taiwanese children. J Microbiol Immunol Infect 52 (2019), 75–80.
180. Red book, 30th ed., 2015, American Academy of Pediatrics.
181. Okazaki, N., Narita, M., Yamada, S., Izumikawa, K., Umetsu, M., Kenri, T., et al. Characteristics of macrolide-resistant Mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro. Microbiol Immunol 45 (2001), 617–620.
182. Parrott, G.L., Kinjo, T., Fujita, J., A compendium for mycoplasma pneumoniae. Front Microbiol, 7, 2016, 513.
183. Hong, K.B., Choi, E.H., Lee, H.J., Lee, S.Y., Cho, E.Y., Choi, J.H., et al. Macrolide resistance of Mycoplasma pneumoniae, South Korea, 2000-2011. Emerg Infect Dis 19 (2013), 1281–1284.
184. Okada, T., Morozumi, M., Tajima, T., Hasegawa, M., Sakata, H., Ohnari, S., et al. Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children. Clin Infect Dis 55 (2012), 1642–1649.
185. Poyhonen, H., Nurmi, M., Peltola, V., Alaluusua, S., Ruuskanen, O., Lahdesmaki, T., Dental staining after doxycycline use in children. J Antimicrob Chemother 72 (2017), 2887–2890.
186. Lee, H., Yun, K.W., Lee, H.J., Choi, E.H., Antimicrobial therapy of macrolide-resistant Mycoplasma pneumoniae pneumonia in children. Expert Rev Anti Infect Ther 16 (2018), 23–34.
187. Carrillo-Marquez, M.A., Hulten, K.G., Hammerman, W., Lamberth, L., Mason, E.O., Kaplan, S.L., Staphylococcus aureus pneumonia in children in the era of community-acquired methicillin-resistance at Texas Children's Hospital. Pediatr Infect Dis J 30 (2011), 545–550.